CHICAGO, May 3, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Citigroup, Inc. (NYSE:C), U.S. Bancorp (NYSE:USB), JPMorgan Chase & Co. (NYSE:JPM), Morgan Stanley (NYSE:MS) and Eastman Chemical Company (NYSE:EMN).
(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday's Analyst Blog:
More Legal Troubles for Citi
United States' third largest bank Citigroup, Inc. (NYSE:C) is on shaky grounds again as it has been sued by U.S. Bancorp (NYSE:USB) in connection with the sale of securities that were allegedly backed by low-quality mortgages. The mortgage backed securities (MBS) were worth $1.08 billion.
These securities were backed by 4,946 mortgage loans. U.S. Bank has accused Citi of violating the contract with the buyers of the securities. U.S. Bank is seeking compensation for the damages, though no amount has been specified. Moreover, it seeks to obtain an order requiring Citi to repurchase the faulty loans.
As per the trustee, the loans carried a high default rate. Due to this, U.S. Bank incurred losses of over $354 million. Further, a forensic review was done on 1,604 of the mortgages underlying the 2007 investment. The review disclosed that approximately 79% of the loans became delinquent.
Similar Charges Earlier
Washington Mutual Inc. – acquired by JPMorgan Chase & Co. (NYSE:JPM) in 2008 – and Citigroup have been legally charged in connection with issues arising out of the sale of MBS by Integer Program LLC for incurring huge losses from mortgage loans.
Further, many other global giants, including Morgan Stanley (NYSE:MS), are battling similar lawsuits related to MBS.
Our Take
Citi currently carries a Zacks Rank #3 (Hold).
Eastman Chemical to Fight Skin Cancer
The producer of LLumar Window Film, Eastman Chemical Company (NYSE:EMN), and The Skin Cancer Foundation have entered into an alliance to help educate consumers on the hazards of the harmful ultraviolet A (UVA) rays on skin that penetrates through glass while driving. Scientific research proclaims that car drivers' left body areas are most exposed to harmful sunrays, and hence are the most affected.
Eastman Chemical is extending its support to The Skin Cancer Foundation's monthly initiative of Skin Cancer Awareness by participating in its "Road to Healthy Skin Tour" presented by Rite Aid. The Tour is expected to have roughly 50 stops along the way at the Rite Aid Stores starting at Hoboken, N.J. on May 14 and ending in Redwood City, Calif., on Aug, 30.
The tour strives to save lives through education about skin cancer prevention through all means of sun protection, detecting skin cancers at the early stage if any, and the need for prompt, effective treatment. For the detection of skin cancer at an early stage, local dermatologists will devote their valuable time in the Tour's 38-foot RV, where they would conduct the screenings at two customized exam rooms.
Local LLumar window film dealers will also enlighten consumers regarding the usefulness of the window film as "sunscreen for your car" on this tour. The Skin Cancer Foundation highly recommends driving under a sun protection program. They promote use of high performance window film for all time protection from harmful UVA rays.
UVA rays of sun are more harmful than UVB rays as they penetrate deep into the skin and can silently accelerate the aging process, cause wrinkles and even skin cancer. UVB rays, however, can immediately blister or burn the skin.
All LLumar window films offers UV protection up to 99% and acts as a "sunscreen" - daily sun protection - which applied once can serve for a length of time. LLumar window films are both of clear and dark types.
Window films are also cost effective as it reduces the interior temperature of a car by upto 30 degrees, thus lowering cooling costs and helping the car to burn less fuel and emit less CO2 gases.
Eastman Chemical currently holds a Zacks Rank #3 (Hold).
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com
SOURCE Zacks Investment Research, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article